Figure 3.

The plasmid and small interfering RNA (siRNA) components of SNS01-T both contribute to its antitumoral activity in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) xenografts. SCID mice were injected subcutaneously with (a) RPMI 8226 or (b) Su-DHL6 cells, and treatments were initiated once tumors became palpable. (a,b) Tumor growth for mice receiving intravenous injections of polyethylenimine nanoparticles twice per week at a dose of 0.375 mg/kg. Nanoparticles contained either: a nonexpressing control plasmid and nontargeting control siRNA (control nanoparticle); the pExp5A plasmid and control siRNA (pExp5A plasmid); control vector and eukaryotic translation initiation factor 5A (eIF5A) siRNA (eIF5A siRNA); or pExp5A and eIF5A siRNA (SNS01-T). Error bars represent the SEM; asterisks indicate statistically significant differences (one-way analysis of variance, Bonferroni posttest; n = 5 per group, P value ≤ 0.05). (c,d) Survival data for the mice treated in a and b. Significant P values, calculated by nonparametric log-rank test comparing control nanoparticle and treatment groups, are indicated. (d) SNS01-T treatment also enhanced survival relative to pExp5A or eIF5A siRNA alone (log-rank test; n = 5 per group, P = 0.0019, 0.0021, respectively) RPMI, Roswell Park Memorial Institute.